There has been no major change of practice in gastrointestinal oncology at the European Society for Medical Oncology (ESMO) symposium 2021, but confirmation that immunotherapy in combination with chemotherapy has become standard of care in several indications. The European Organisation for Research and Treatment of Cancer (EORTC) Gastrointestinal Track Cancer Group has selected important phase II and III trials presented during the symposium across all gastrointestinal cancers as well as early reports on new drugs or new combinations that may change practice in the future.

Cambridge University Hospitals NHS Foundation Trust Addenbrooke's Hospital Cambridge UK

Caritasklinikum Saarbrucken Germany

Department of Comprehensive Cancer Care Masaryk Memorial Cancer Institute and Faculty of Medicine Masaryk University Brno; Department of Pharmacology Faculty of Medicine Masaryk University Brno Czech Republic

Department of Internal Medicine Johannes Gutenberg University Mainz Germany

Department of Medical Oncology Institut Jules Bordet Université Libre de Bruxelles Brussels Belgium

Department of Oncology Division of Medical Oncology Lausanne University Hospital Lausanne Switzerland

Department of Oncology Geneva University Hospital Geneva Switzerland; Swiss Cancer Center Leman University of Geneva Lausanne Switzerland

Department of Oncology Haematology and Palliative Care Asklepios Klinik Altona Asklepios Tumorzentrum Hamburg Hamburg Germany

Department of Oncology Haematology and Palliative Care Asklepios Klinik Altona Asklepios Tumorzentrum Hamburg Hamburg Germany; European Organisation for Research and Treatment of Cancer Brussels Belgium

Department of Oncology Universitair Ziekenhuis Antwerpen Antwerp Belgium

Division of Cancer Sciences University of Manchester Manchester UK; Department of Medical Oncology The Christie NHS Foundation Trust Manchester UK

Division of Oncology Rambam Health Care Campus Rappaport Faculty of Medicine Technion Haifa Israel

GI Oncology Medical Oncology Department Institut Curie Saint Cloud Versailles Saint Quentin University Saint Cloud France

Hospital Universitario de Navarra Barcelona Spain

Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology Warsaw Poland

Sarah Cannon Research Institute London UK

Zobrazit více v PubMed

Janjigian Y.Y., Ajani J.A., Moehler M., et al. LBA7 Nivolumab (NIVO) plus chemotherapy (Chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 study. Ann Oncol. 2021;32:S1329–S1330.

Stein A., Paschold L., Tintelnot J., et al. LBA54 Ipilimumab or FOLFOX in combination with nivolumab and trastuzumab in previously untreated HER2 positive locally advanced or metastastic esophagogastric adenocarcinoma (EGA): results of the randomized phase II INTEGA trial (AIO STO 0217) Ann Oncol. 2021;32:S1331. PubMed

Bang Y.J., van Cutsem E., Feyereislova A., et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–697. PubMed

Catenacci D.V., Park H., Shim B.Y., et al. 1379P Margetuximab (M) with retifanlimab (R) in HER2+, PD-L1+ 1st-line unresectable/metastatic gastroesophageal adenocarcinoma (GEA): MAHOGANY cohort A. Ann Oncol. 2021;32:S1043–S1044.

Shen L., Lu Z.-H., Wang J.-Y., et al. LBA52 Sintilimab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced or metastatic esophageal squamous cell cancer: first results of the phase III ORIENT-15 study. Ann Oncol. 2021;32:S1330.

Xu J., Jiang H., Pan Y., et al. LBA53 Sintilimab plus chemotherapy (chemo) versus chemo as first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-16): first results of a randomized, double-blind, phase III study. Ann Oncol. 2021;32:S1331.

Qi C., Qin Y., Liu D., et al. 1372O CLDN 18.2-targeted CAR-T cell therapy in patients with cancers of the digestive system. Ann Oncol. 2021;32:S1040.

van Cutsem E., Di Bartolomeo M., Smyth E., et al. LBA55 Primary analysis of a phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after a trastuzumab-containing regimen. Ann Oncol. 2021;32:S1332.

Shitara K., Bang Y.-J., Iwasa S., et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382:2419–2430. PubMed

Deng Y., Chi P., Lan P., et al. Modified FOLFOX6 with or without radiation in neoadjuvant treatment of locally advanced rectal cancer: Final results of the Chinese FOWARC multicenter randomized trial. J Clin Oncol. 2018;36 3502-3502. PubMed PMC

Ding P.-R., Wang X.-Z., Li Y.-F., et al. LBA22 Neoadjuvant chemotherapy with oxaliplatin and capecitabine versus chemoradiation with capecitabine for locally advanced rectal cancer with uninvolved mesorectal fascia (CONVERT): Initial results of a multicenter randomised, open-label, phase III trial. Ann Oncol. 2021;32:S1296.

Cremolini C., Rossini D., Antoniotti C., et al. LBA20 FOLFOXIRI plus bevacizumab (bev) plus atezolizumab (atezo) versus FOLFOXIRI plus bev as first-line treatment of unresectable metastatic colorectal cancer (mCRC) patients: results of the phase II randomized AtezoTRIBE study by GONO. Ann Oncol. 2021;32:S1294–S1295.

Mulcahy M.F., Salem R., Mahvash A., et al. LBA21 Radioembolization with chemotherapy for colorectal liver metastases: a randomized, open-label, international, multicenter, phase III trial (EPOCH study) Ann Oncol. 2021;32:S1295. PubMed PMC

Pietrantonio F., Morano F., Lonardi S., et al. 383O MAYA trial: Temozolomide (TMZ) priming followed by combination with low-dose ipilimumab and nivolumab in patients with microsatellite stable (MSS), MGMT silenced metastatic colorectal cancer (mCRC) Ann Oncol. 2021;32:S530–S531. PubMed PMC

Hong D.S., Fakih M.G., Strickler J.H., et al. KRASG12C inhibition with sotorasib in advanced solid tumors. N Engl J Med. 2020;383:1207–1217. PubMed PMC

Weiss J., Yaeger R.D., Johnson M.L., et al. LBA6 KRYSTAL-1: Adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (Pts) with colorectal cancer (CRC) harboring a KRASG12C mutation. Ann Oncol. 2021;32:S1294.

Fakih M., Falchook G.S., Hong D.S., et al. 434P CodeBreaK 101 subprotocol H: Phase Ib study evaluating combination of sotorasib (Soto), a KRASG12C inhibitor, and panitumumab (PMab), an EGFR inhibitor, in advanced KRAS p.G12C-mutated colorectal cancer (CRC) Ann Oncol. 2021;32:S551.

Seligmann J., Fisher D.J., Brown L.C., et al. 382O Inhibition of WEE1 is effective in TP53 and RAS mutant metastatic colorectal cancer (mCRC): a randomised phase II trial (FOCUS4-C) comparing adavosertib (AZD1775) with active monitoring. Ann Oncol. 2021;32:S530. PubMed PMC

Siena S., Di Bartolomeo M., Raghav K., et al. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2021;22:779–789. PubMed

Siena S., Raghav K., Masuishi T., et al. 386O Exploratory biomarker analysis of DESTINY-CRC01, a phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd, DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC) Ann Oncol. 2021;32:S532. PubMed

Valle J.W., Kelley R.K., Nervi B., Oh D.Y., Zhu A.X. Biliary tract cancer. Lancet. 2021;397:428–444. PubMed

Perkhofer L., Striefler J.K., Sinn M., et al. LBA10 Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer: Final results of the NIFE-trial (AIO-YMO HEP-0315), a randomized phase II study of the AIO biliary tract cancer group. Ann Oncol. 2021;32:S1282. PubMed

Wang-Gillam A., Li C.P., Bodoky G., et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016;387:545–557. PubMed

Yoo C., Kim K.-P., Kim I., et al. Liposomal irinotecan (nal-IRI) in combination with fluorouracil (5-FU) and leucovorin (LV) for patients with metastatic biliary tract cancer (BTC) after progression on gemcitabine plus cisplatin (GemCis): multicenter comparative randomized phase 2b study. J Clin Oncol. 2021;39 4006-4006. PubMed

Baudin E., Goichot B., Berruti A., et al. 567O First international randomized study in malignant progressive pheochromocytoma and paragangliomas (FIRSTMAPPP): an academic double-blind trial investigating sunitinib. Ann Oncol. 2021;32:S621.

Raymond E., Dahan L., Raoul J.-L., et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:501–513. PubMed

Baudin E., Horsch D., Singh S., et al. 1096O Lanreotide autogel/depot (LAN) in patients with advanced bronchopulmonary (BP) neuroendocrine tumors (NETs): results from the phase III SPINET study. Ann Oncol. 2021;32:S906.

Caplin M.E., Pavel M., Ćwikła J.B., et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371:224–233. PubMed

Rinke A., Müller H.-H., Schade-Brittinger C., et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol. 2009;27:4656–4663. PubMed

Garcia-Carbonero R., Benavent M., Jiménez Fonseca P., et al. A phase II/III randomized double-blind study of octreotide acetate LAR with axitinib versus octreotide acetate LAR with placebo in patients with advanced G1-G2 NETs of non-pancreatic origin (AXINET trial-GETNE-1107) J Clin Oncol. 2021;39 360-360.

Garcia-Carbonero R., Benavent M., Fonseca P.J., et al. 1097O the AXINET trial (GETNE1107): axitinib plus octreotide LAR improves PFS by blinded central radiological assessment vs placebo plus octreotide LAR in G1-2 extrapancreatic NETs. Ann Oncol. 2021;32:S907–S908.

Versteijne E., Suker M., Groothuis K., et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC trial. J Clin Oncol. 2020;38:1763–1773. PubMed PMC

Van Eijck C.H.J., Versteijne E., Suker M., et al. Preoperative chemoradiotherapy to improve overall survival in pancreatic cancer: long-term results of the multicenter randomized phase III PREOPANC trial. J Clin Oncol. 2021;39 4016-4016.

Seufferlein T., Uhl W., Algül H., et al. LBA56 Perioperative or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer: results of the NEONAX trial, a randomized phase II AIO study. Ann Oncol. 2021;32:S1283–S1346.

Tempero M., O’Reilly E., van Cutsem E., et al. LBA-1 Phase 3 APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P + Gem) vs gemcitabine (Gem) alone in patients with resected pancreatic cancer (PC): updated 5-year overall survival. Ann Oncol. 2021;32:S226.

Conroy T., Hammel P., Hebbar M., et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379:2395–2406. PubMed

Conroy T., Hammel P., Turpin A., et al. LBA57 Unicancer PRODIGE 24/CCTG PA6 trial: updated results of a multicenter international randomized phase III trial of adjuvant mFOLFIRINOX (mFFX) versus gemcitabine (gem) in patients (pts) with resected pancreatic ductal adenocarcinomas (PDAC) Ann Oncol. 2021;32:S1334.

Valle J.W., Palmer D., Jackson R., et al. Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. J Clin Oncol. 2014;32:504–512. PubMed

Ludford K., Raghav K., Murphy M.A.B., et al. 1758O Neoadjuvant pembrolizumab in localized/locally advanced solid tumors with mismatch repair deficiency. Ann Oncol. 2021;32:S1210.

Sorbye H., Venizelos A., Elvebakken H., et al. 1100MO Molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms. Ann Oncol. 2021;32:S910–S911. PubMed PMC

Cancer Genome Atlas Research Network Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202–209. PubMed PMC

Kopp C., Lorenzen S., Gaiser T., et al. 1430P Frequency of PD-L1 positivity and microsatellite instability (MSI) in the DANTE trial: perioperative atezolizumab with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma. a randomized, open-label phase IIb trial of the German gastric group at the AIO and SAKK. Ann Oncol. 2021;32:S1069–S1070.

Al-Batran S.-E., Lorenzen S., Homann N., et al. 1429P Pathological regression in patients with microsatellite instability (MSI) receiving perioperative atezolizumab in combination with FLOT vs. FLOT alone for resectable esophagogastric adenocarcinoma: results from the DANTE trial of the German gastric group at the AIO and SAKK. Ann Oncol. 2021;32:S1069.

Mirallas O., López-Valbuena D., García-Illescas D., et al. 1431P Descriptive analysis and prognostic factors of microsatellite instability (MSI) gastric cancer patients (pts) compared to microsatellite stable (MSS) pts in a tertiary hospital. Ann Oncol. 2021;32:S1070.

Banales J.M., Cardinale V., Carpino G., et al. Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA) Nat Rev Gastroenterol Hepatol. 2016;13:261–280. PubMed

Pamiparib and low dose temozolomide in patients with platinum sensitive biliary tract cancer (PAMICC) https://clinicaltrials.gov/ct2/show/NCT04796454 Available at.

Zhang J., Wang A., Li Z., et al. 334TiP A phase I trial of niraparib plus anlotinib in advanced solid tumors with homologous recombination repair (HRR) gene mutations. Ann Oncol. 2021;32:S512.

Busset M.D.D., Shaib W.L., Mody K., et al. 47P Derazantinib for patients with intrahepatic cholangiocarcinoma harboring FGFR2 fusions/rearrangements: primary results from the phase II study FIDES-01. Ann Oncol. 2021;32:S376–S381.

Park H., Bekaii-Saab T., Kim S., et al. 1437TiP Phase Ib/II, open label, dose escalation and expansion trial of tucatinib in combination with trastuzumab and oxaliplatin-based chemotherapy in patients with unresectable or metastatic HER2+ gastrointestinal cancers (trial in Progress) Ann Oncol. 2021;32:S1073–S1074.

Vogel A., Behringer D.M., Bröckling S., et al. 1871TiP PLATON – “Platform for analyzing targetable tumor mutations”: a pilot study. Ann Oncol. 2021;32:S1255.